D. Patt

发表

Achieving the Meaningful Use Standard: A Model for Implementing Change Within Medical Practices.

D. Fryefield, Stuart Staggs, William Herman, 2014, Journal of oncology practice.

Evaluating patient-specific neoadjuvant regimens for breast cancer via a mathematical model constrained by quantitative magnetic resonance imaging data

Angela M. Jarrett, David A. Ekrut, Anum S. Kazerouni, 2020, Neoplasia.

Repeatability, reproducibility, and accuracy of quantitative mri of the breast in the community radiology setting

T. Yankeelov, Hakmook Kang, D. Patt, 2018, Journal of magnetic resonance imaging : JMRI.

More Medicine, Fewer Clicks: How Informatics Can Actually Help Your Practice.

Joshua C. Mandel, David A. Kreda, J. Warner, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

D. Schadendorf, J. Wolchok, F. Hodi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimal Control Theory for Personalized Therapeutic Regimens in Oncology: Background, History, Challenges, and Opportunities

Angela M. Jarrett, G. Biros, T. Yankeelov, 2020, Journal of clinical medicine.

Magnetization Transfer MRI of Breast Cancer in the Community Setting: Reproducibility and Preliminary Results in Neoadjuvant Therapy

Angela M. Jarrett, David A. Ekrut, T. Yankeelov, 2019, Tomography.

Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC).

D. Patt, J. O’Shaughnessy, J. Pippen, 2009 .

Cancer Informatics in 2018: The Mysteries of the Cancer Genome Continue to Unravel, Deep Learning Approaches the Clinic, and Passive Data Collection Demonstrates Utility

J. Warner, D. Patt, 2019, Yearbook of Medical Informatics.

Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.

G. Hortobagyi, S. Fang, D. Patt, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrating mechanism-based modeling with biomedical imaging to build practical digital twins for clinical oncology.

T. Yankeelov, D. Patt, G. Lorenzo, 2022, Biophysics reviews.

Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update

S. Chandarlapaty, N. Lin, S. Temin, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.

R. Schilsky, G. Lyman, D. Patt, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Informatics in 2019: Deep Learning Takes Center Stage

J. Warner, D. Patt, 2020, Yearbook of Medical Informatics.

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

E. Winer, E. Perez, S. Chandarlapaty, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update

S. Chandarlapaty, N. Lin, S. Temin, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathways, outcomes, and costs in colon cancer: retrospective evaluations in 2 distinct databases.

D. Patt, R. Beveridge, T. Cartwright, 2011, The American journal of managed care.

The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting.

B. Bolinder, D. Patt, E. Jabbour, 2015, Clinical lymphoma, myeloma & leukemia.

Treatment of metastatic breast cancer with 𝑛𝑎𝑏-paclitaxel in the community practice setting: a US Oncology survey.

D. Patt, D. Corzo, D. Rembert, 2015, The Journal of community and supportive oncology.

A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting

D. Patt, D. Bhowmik, Sumati Rao, 2014 .

Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC)

J. Baselga, D. Patt, S. Isakoff, 2018, Clinical Trials.

Telemedicine in Community Cancer Care: How Technology Helps Patients With Cancer Navigate a Pandemic

D. Patt, M. Neubauer, L. Wilfong, 2021, JCO oncology practice.

Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors

D. Patt, T. Okon, N. Markward, 2020, JCO clinical cancer informatics.

The Road of Mentorship.

D. Patt, R. Prabhu, Kelly J Cooke, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

New Landscape: Physician Compensation.

Julia E Tomkins, L. Bosserman, D. Patt, 2020, JCO oncology practice.

Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer

G. Lyman, P. Fox, D. Patt, 2018, Clinical breast cancer.

Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer

G. Lyman, D. Patt, J. Crawford, 2019, Supportive Care in Cancer.

Analysis of simplicial complexes to determine when to sample for quantitative DCE MRI of the breast

Anum S. Kazerouni, T. Yankeelov, D. Patt, 2022, Magnetic resonance in medicine.

Acute myeloid leukemia (AML) in older women after adjuvant breast cancer therapy.

G. Hortobagyi, D. Patt, S. Giordano, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

3-54 Late Cardiac Mortality and Morbidity in Early-Stage Breast Cancer Patients After Breast-Conservation Treatment

D. Patt, S. Giordano, 2007 .

Cancer Informatics 2022: Real-World Data Yields Important Insights into the Conduct of Clinical Trials and Registries

J. Warner, D. Patt, M. Rooney, 2022, Yearbook of Medical Informatics.

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

C. Hudis, J. Baselga, H. Rugo, 2017, Clinical Cancer Research.

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Mark Yoffe, Debra Patt, D. Patt, 2011, The New England journal of medicine.

Clinical Challenges and Opportunities With Current Electronic Health Records: Practicing Oncologists' Perspective.

L. Bosserman, D. Patt, P. Stella, 2018, Journal of oncology practice.

Cardiac morbidity of adjuvant radiotherapy for breast cancer.

J. Goodwin, G. Hortobagyi, T. Buchholz, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

H. Rugo, H. Wildiers, D. Patt, 2020, Breast Cancer Research and Treatment.

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

H. Rugo, M. Gnant, H. Iwata, 2020, Clinical breast cancer.

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

E. Winer, S. Chandarlapaty, N. Lin, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

E. Winer, E. Perez, S. Chandarlapaty, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer

C. Obasaju, M. Socinski, D. Patt, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and efficacy of nab-paclitaxel (nab-P) in patients (pts) with metastatic breast cancer (MBC): Real-world results from a U.S. health insurance database.

D. Patt, C. Enger, D. Corzo, 2014 .

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial.

D. Patt, J. O’Shaughnessy, J. Pippen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting

Angela M. Jarrett, Anum S. Kazerouni, T. Yankeelov, 2021, Breast cancer research : BCR.

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

V. Karantza, D. Patt, R. O'Regan, 2021, Clinical Cancer Research.

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.

G. Lyman, D. Patt, L. Asmar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Paclitaxel in Breast Cancer

D. Patt, S. Giordano, M. Gauthier, 2006, Women's health.

Telehealth in Oncology: ASCO Standards and Practice Recommendations

D. Patt, R. Zon, T. Mulvey, 2021, JCO oncology practice.

Using Clinical Informatics to Navigate a Crisis: How Technology and Policy Change Can Influence Cancer Care Delivery.

D. Patt, 2020, JCO Clinical Cancer Informatics.

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

P. Fasching, L. Pusztai, C. Denkert, 2022, The New England journal of medicine.

Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.

D. Patt, Clara C. Chen, R. Dhanda, 2013, Journal of oncology practice.

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.

Jonathan M Marron, Laura A. Levit, R. Schilsky, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Math, magnets, and medicine: enabling personalized oncology

Angela M. Jarrett, T. Yankeelov, D. Patt, 2021, Expert review of precision medicine and drug development.

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

Sarat Chandarlapaty, Naren Ramakrishna, E. Winer, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

G2 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial

D. Patt, J. O’Shaughnessy, J. Pippen, 2009 .

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.

P. Nuciforo, D. Patt, L. de la Peña, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized control trial of meditation compared to music listening to improve cognitive function for breast cancer survivors: Feasibility and acceptability.

S. Kesler, D. Patt, H. Becker, 2020, Complementary therapies in clinical practice.

A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).

V. Karantza, D. Patt, R. O'Regan, 2020 .

Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity

Gil Alterovitz, Matvey B Palchuk, Feichen Shen, 2020, J. Am. Medical Informatics Assoc..

HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes

N. Robert, D. Patt, Hans-Peter Goertz, 2017, Drugs - Real World Outcomes.

The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis

D. Patt, C. Enger, D. Corzo, 2015, BMC Cancer.

Considerations to increase rates of breast cancer screening across populations.

D. Patt, C. Harris, K. Patel, 2022, The American journal of managed care.

249PAnalysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease

J. Baselga, H. Rugo, H. Wildiers, 2017 .

Abstract CT044: MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease

J. Baselga, H. Rugo, H. Wildiers, 2017 .

Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases.

D. Patt, R. Beveridge, T. Cartwright, 2011, Journal of oncology practice.

D. Patt, J. O’Shaughnessy, J. Pippen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Telemedicine for cancer care: implementation across a multicenter community oncology practice.

D. Patt, L. Wilfong, R. S. Paulson, 2020, The American journal of managed care.

Understanding Utilization Management Policy: How to Manage This Increasingly Complex Environment in Collaboration and With Better Data.

D. Patt, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Defining cancer care quality or delivering quality cancer care?

D. Patt, R. Beveridge, Matthew E. Brow, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Benchmarks for value in cancer care: an analysis of a large commercial population.

D. Patt, R. Beveridge, B. Brooks, 2011, Journal of oncology practice.

Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis.

D. Patt, A. Brufsky, R. Layman, 2022, Clinical breast cancer.

Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis

Sarah Avery, Thomas E Yankeelov, Hakmook Kang, 2017, Journal of medical imaging.

Quantitative magnetic resonance imaging and tumor forecasting of breast cancer patients in the community setting

David A. Ekrut, Anum S. Kazerouni, T. Yankeelov, 2021, Nature Protocols.

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, M. Gnant, H. Iwata, 2023, European journal of cancer.

How to begin a survivorship program in your community oncology practice

D. Patt, Sabrina Q. Mikan, Sara Toth, 2013 .

MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.

J. Baselga, H. Rugo, H. Wildiers, 2016 .

Abstract OT1-03-09: FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC)

J. Baselga, D. Patt, S. Isakoff, 2016 .

FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer.

J. Baselga, D. Patt, S. Isakoff, 2015 .

Using Big Data and Predictive Analytics to Determine Patient Risk in Oncology.

Ravi B. Parikh, C. Mermel, D. Patt, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Implementation of Electronic Patient-Reported Outcomes for Symptom Monitoring in a Large Multisite Community Oncology Practice: Dancing the Texas Two-Step Through a Pandemic.

E. Basch, D. Patt, L. Wilfong, 2021, JCO clinical cancer informatics.

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

P. Fasching, L. Pusztai, C. Denkert, 2022, Cancer Research.

The rate of breast fibroglandular enhancement during dynamic contrast-enhanced MRI reflects response to neoadjuvant therapy.

T. Yankeelov, D. Patt, A. Sorace, 2021, European journal of radiology.

Machine Learning and Real-World Data: More than Just Buzzwords.

D. Patt, Z. Bakouny, 2021, JCO Clinical Cancer Informatics.

Patient-Reported Outcomes, Digital Health, and the Quest to Improve Health Equity.

C. Snyder, D. Patt, G. Thanarajasingam, 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Treatment patterns in HER2+/HR+ postmenopausal women with metastatic breast cancer initiating first-line treatment in a community oncology setting in the US

T. Delea, D. Patt, K. Sail, 2013 .

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

D. Patt, J. O’Shaughnessy, J. Pippen, 2011, The New England journal of medicine.

Vitamin D levels, triple-negative histology, and geography in breast cancer: A retrospective analysis of a large database of oncology practices in the United States.

D. Patt, J. O’Shaughnessy, E. Epstein, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma

D. Patt, C. Yasenchak, M. Yap, 2015, Leukemia & lymphoma.

Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting.

Ya-Chen Tina Shih, S. Ramsey, D. Patt, 2013, The oncologist.

Women in oncology: progress, challenges, and keys to success.

E. Felip, D. Patt, K. Reeder-Hayes, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.